

MAY 27 2005 Serial No. 10/602,215
PC 21501B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Kulkarni et al. EXAMINER: Cook, Rebecca
SERIAL NO.: 10/602,215 ART UNIT: 1614
FILED: 06/24/2003 PAPER NO.:
FOR: LIQUID PHARMACEUTICAL COMPOSITIONS

AFTER-FINAL AMENDMENT PURSUANT TO 37 CFR § 1.116
REQUIRED SUBMISSION UNDER 37 CFR § 1.114

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Examiner:

In response to a final Office action mailed February 28, 2005, please amend the above-identified application as indicated in a listing of claims that begins on page 2 of this paper. Applicant's remarks and arguments begin on page 5 of this paper. This amendment accompanies a Request for Continued Examination (RCE) under CFR §1.114

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☐ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

FACSIMILE

- ☒ transmitted by facsimile to the Patent and Trademark Office, telephone number (703) 872-9306.

Date: May 27, 2005

Signature


Matthew J. Russo
(type or print name of person certifying)

After Final Amendment—page 1 of 9